- Conditions
- Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
- Interventions
- Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (cold-stored 15 days), Aspirin, Clopidogrel
- Drug
- Lead sponsor
- Bloodworks
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 49
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Interventions
- placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Drug · Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
- Conditions
- Acute Coronary Syndrome, High Bleeding Risk
- Interventions
- BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
- Device · Drug
- Lead sponsor
- Biosensors Europe SA
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more
- Conditions
- Bleeding Complications
- Interventions
- Clopidogrel, Prasugrel, Tricagrelor
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Coronary Syndrome
- Interventions
- Video Capsule Endoscopy
- Procedure
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Coronary Disease, Angina Unstable
- Interventions
- Clopidogrel, acetylsalicyclic acid (ASA)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25,086 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Stable Angina
- Interventions
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Coronary Artery Disease
- Interventions
- Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
- Drug
- Lead sponsor
- Baim Institute for Clinical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 178
- States / cities
- Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Interventions
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Drug · Device
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • New York, New York
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Psoriasis (PsO), Psoriatic Arthritis (PsA)
- Interventions
- Aspirin, Clopidogrel, Placebo
- Drug · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Coronary Artery Disease
- Interventions
- 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
- Drug · Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,009 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 89
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
- Conditions
- Peripheral Arterial Disease, Endovascular Procedures
- Interventions
- Aspirin, Clopidogrel
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Coronary Artery Disease
- Interventions
- Placebo Arm, Thienopyridine Therapy, Surveillance Arm
- Drug · Device
- Lead sponsor
- Medtronic Vascular
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 2,272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Anderson, South Carolina
- Conditions
- Coronary Artery Disease, Angina Pectoris
- Interventions
- Percutaneous Coronary Intervention, Coronary stent, Clopidogrel
- Procedure · Device · Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Stroke, Transient Ischemic Attack
- Interventions
- Septal Occluder Device, Antiplatelet Medical Therapy
- Device · Drug
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Interventions
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Diagnostic Test
- Lead sponsor
- Hikari Dx, Inc.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Clopidogrel, Acetylsalicylic acid (ASA)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Davenport, Iowa • Dallas, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- Clopidogrel & Aspirin, Prasugrel & Aspirin, Placebo & Aspirin
- Drug
- Lead sponsor
- Cordis US Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
- Interventions
- Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Salem, Massachusetts
- Conditions
- Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
- Interventions
- Polypill, Usual Care (individual medications prescribed by primary cardiologist)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Clopidogrel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Platelet Aggregation, Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Accriva Diagnostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Baltimore, Maryland
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Interventions
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 91 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas